Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q1 FY27 Earnings Presentation
24 slides from Mankind Pharma's earnings presentation, Jul 30, 2026
Slide 1: Stock exchange cover letter for investor presentation
July 30, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Ref: Regulation 30 of the
Slide 2: Investor Presentation Q1 FY27
ig Mankindil> INVESTOR PRESENTATION Ql FY27 July 2026
Slide 3: Index
Index 03 Additional Information • Mankind Pharma at a Glance (FY26) • Key Milestones • Expansion in Specialty and Super Specialty Segments 01 Financial Performance • Financials - Steady Growth Trajectory • Key Financials – Q1 FY27 • Shareholding Pattern • P & L Highlights – Q1 FY27 • Annexures • Key
Slide 4: Financial Performance
ig Mankindii> Sirois Life Financial Performance
Slide 5: Revenue grew ~13% YoY with EBITDA margins improving by 250 bps to 26.3%
Mr. Rajeev Juneja Vice Chairman & Managing Director Segmental Revenue Break - Up • Revenue grew ~13% YoY with EBITDA margins improving by 250 bps to 26.3% • Overall domestic business (ex CH) grew by 11.0% led by: Double digit growth in Mankind domestic business with 15.8% growth in 15% 7% Chronic
Slide 6: Key Financials – Q1 FY27
INR Cr Q1 FY27 Q1FY26 YoY Growth Q4FY26 QoQ Growth Revenue from Operations (A=B+C) 4,031 3,570 12.9% 3,443 17.1% Domestic Business (B) 3,426 3,101 10.5% 2,886 18.7% i. Domestic Business (ex CH) 3,180 2,864 11.0% 2,673 19.0% ii. Consumer Healthcare (CH) 246 237 3.9% 213 15.5% Exports Business (C) 605
Slide 7: Key Financial Metrics – Q1 FY27
Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 CFO to CAPEX as % 80% 89% 99% 77% 4.3% 5.2% 3.6% 4.9% EBITDA of Rev With BSV With BSV With BSV With BSV Acquisition Acquisition Acquisition Acquisition 723 263 40% 41% 42% 43% 814 761 187 184 460 797 91 593 128 163 546 840 840 817 125 127 127 1
Slide 8: Business Updates
ig Mankindil> Jeroing Life Business Updates
Slide 9: Strong Growth in Domestic (ex-CH) Revenue
Strong Growth in Domestic (ex-CH) Revenue1,2 INR Cr 11,338 9,866 8,741 7,761 2,864 3,180 FY23 FY24 FY25 FY26 Q1FY26 Q1FY27 Domestic revenue (ex- CH) increased 11.0% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business Secondary sales3 growth
Slide 10: Consistent focus to increase chronic contribution
Consistent focus to increase chronic contribution Overall Chronic Growth 1.4x 1.2x 1.1x2 1.4x2 1.0x2 41.2 40.4 40.0 39.6 16.8 15.8 39.0 38.8 38.3 38.5 14.7 13.5 13.6 13.4 36.6 11.9 9.7 9.8 10.7 35.2 FY24 FY25 FY26 Q1FY26 Q1FY27 FY24 FY25 FY26 Q1FY26 Q1FY27 IPM Chronic Share % Mankind Chronic Share %
Slide 11: High Ranks across Acute and Chronic Areas
High Ranks across Acute and Chronic Areas FY26 - Sales Mix representing Diversified Therapy Presence Rank in CVM MS% FY 21-26 CAGR Key Therapy Areas (FY26) (FY26) Mankind1 IPM 2% 11% 17% Chronic therapies 3 4.3% 14.3% 11.4% Cardiovascular Anti-Infectives Cardiovascular 4 5.5% 17.3% 11.1% 4% Gynaecol
Slide 12: Consumer Healthcare Segment Revenue
Consumer Healthcare Segment Revenue (INR Cr) EBITDA % 19.9% 19.0% 18.7%1 18.0% 18.6% 879 809 692 706 4% 237 246 FY23 FY24 FY25 FY26 Q1FY26 Q1FY27 Revenue growth of 4% YoY in Q1FY27 partly impacted by base effect of discontinued cash and carry business Despite softer growth, we gained market shar
Slide 13: Strategically selected national and regional brand ambassadors
Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Sunny Manasvi Leone Mamgai Market Share – 28% #1 Anushka Kajal Srabanti Pregnancy Test Kit Brand Sharma Aggarwal Chatterjee Market Share –
Slide 14: Revenue from Exports
Revenue from Exports (INR Cr) 1 2,061 1,532 813 605 469 296 FY23 FY24 FY25 FY26 Q1FY26 Q1FY27 Revenue from International business registered healthy growth of 29% YoY in Q1FY27 Mankind (excluding BSV) has launched 1 new products in Q1FY27 taking the total launched products to 49 in US 1. Denotes
Slide 15: Additional Information
ig Mankindii> Serving Life y/ Additional Information
Slide 16: Mankind Pharma at a Glance (FY26)
Rank in Prescriptions over Rank by volume in Rank by value in IPM1 / Consumer Healthcare brands Market the last nine years1 IPM1 Gynaecology ranked #1 in their categories1 Leadership Brand families1 worth FY26 Revenue FY26 Domestic Revenue Mar’26 Field force2 INR 50/100 Cr+ Scale Revenue CAGR FY21-2
Slide 17: Key Milestones
1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 2025-26 Entered into in-licensing Acquired 1. Acquired Rivotril agreements with: 100% stake in Successfully listed BSV Limited in CNS from Roche Commenced Entered chronic Entered Acquired brands 1. Astra Zeneca - Paonta Sahib on NSE and BSE 2. Udaipur
Slide 18: Expansion in Specialty and Super Specialty Segments
Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty Targeted Medical Practitioners Targeted Medical Practitioners Targeted Medical Practitioners GP CP MD MD DM KOL GT MT ECOM MD DM KOL INR 11,338 Cr 28%/ 39% ~INR 879
Slide 19: Financials - Steady Growth Trajectory
Revenue (INR Cr) Strong Growth in Domestic Revenue (INR Cr) 18% 15% CAGR CAGR 14,278 12,207 12,217 10,260 10,675 8,749 9,447 7,782 8,453 7,595 6,214 6,028 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 EBITDA (INR Cr) and Margin % (2) 26.7% 25.8% 21.9% 24.6% 25.9%3 25.4%4 3,6294 3 3,159
Slide 20: Shareholding Pattern
BSE Ticker 543904 1.3% 1.8% 13.8% NSE Symbol MANKIND # of Shares outstanding1 41,29,95,978 10.5% Share Price2 2,546.50 Market Cap. (INR Cr)1 1,05,169 72.6% % Free Float3 26.4% Free Float Market Cap. (INR Cr) 27,765 Promoters & Promoter Group FPI & Bodies Corporate Mutual Funds Retail Industry Pharma
Slide 21: Annexures: Formulas and definitions
• ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash. • Adjusted ROCE = (Adjusted EBIT for the year )/ (A
Slide 22: Q1 FY27 Earnings Call Details
Date 30th July, 2026 Time 06:30 PM – 07:30 PM IST Link Zoom Call https://us06web.zoom.us/webinar/register/WN_Bgx754b5TeyVRHqaKOSIlw#/registration 21
Slide 23: Disclaimer
The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goal”, “likely”, “project”
Slide 24: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Prakash Agarwal President Strategy 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com